Jonathan Chung to Urinary Bladder Neoplasms
This is a "connection" page, showing publications Jonathan Chung has written about Urinary Bladder Neoplasms.
Connection Strength
1.401
-
Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure. Eur J Cancer. 2018 06; 96:128-130.
Score: 0.459
-
Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. J Natl Cancer Inst. 2021 01 04; 113(1):48-53.
Score: 0.138
-
Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. Eur Urol Focus. 2021 Nov; 7(6):1339-1346.
Score: 0.135
-
Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study. Clin Genitourin Cancer. 2020 10; 18(5):e543-e556.
Score: 0.130
-
Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. Eur Urol. 2020 04; 77(4):548-556.
Score: 0.129
-
Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol. 2020 05; 77(5):636-643.
Score: 0.129
-
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. Eur Urol. 2020 04; 77(4):439-446.
Score: 0.128
-
Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol. 2018 12 01; 36(34):3353-3360.
Score: 0.119
-
Targetable gene fusions and aberrations in genitourinary oncology. Nat Rev Urol. 2020 11; 17(11):613-625.
Score: 0.034